August 3, 2014 | Israeli pharmaceutical company BioBlast announced that it raised $37 million in its NASDAQ IPO last week. The company priced 3,200,000 ordinary shares at $11 per share making gross proceeds of $35.2 million. The company also granted the underwriters 30 days to purchase up to 480,000 additional shares. BioBlasts offering, trading under the ticker ORPN is expected to close on August 5, 2014, subject to customary closings. BioBlast is an Israeli clinical stage biotechnology company founded in 2012 developing treatments for rare and ultra-rare genetic diseases.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023

Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023

Israel Opens Its First Satellite Observatory
February 02, 2023

Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments